+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global Erythropoietin - Stimulating Agents market - Growth Trends, and Forecast 2017 - 2022

  • ID: 4388600
  • Report
  • Region: Global
  • 211 pages
  • Mordor Intelligence
1 of 3
Erythropoietin stimulating agents are drugs that are similar to Erythropoietin. This stimulates the growth of red blood cells. ESAs have been approved for the treatment of anaemia due to chronic kidney failure, chemotherapy, HIV, and also for reduced red blood cells during critical surgical procedures. Recombinant Erythropoietin is a biotechnologically derived Erythropoietin and is most widely used. Erythropoietin stimulating agents are utilized to maintain haemoglobin at a low level such that transfusion is minimized but an individual’s need is fulfilled.

The increasing incidence and prevalence of anaemia, HIV and cancer and increased application of erythropoietin for various cancer and HIV treatment is propelling the growth of the market. However, stringent regulatory guidelines are turning out to be a restraint for the market.

The erythropoietin stimulating agents market have been segmented based on type and application. The segmentation based on type includes Epoetin - alpha, Epoetin - Beta, Epoetin - Omega, Epoetin - Delta, and Darbepoetin - Alpha. The segmentation based on applications includes cancer chemotherapy, Anemia, Renal disorder, anti-retroviral treatment, neural diseases and others. Darbepoetin is one of the latest group of products that have been marketed but the market for the same is expected to grow rapidly during the forecast period.

The market have been geographically segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The North America have been subdivided into USA, Canada and Mexico. The market in Europe have been subdivided into UK, Germany, France, Italy, Spain, and rest of Europe. The market in Asia-Pacific have been subdivided into Japan, China, India, South Korea, Australia & New Zealand, and rest of Asia-Pacific. The Middle East and Africa have been subdivided into GCC countries, South Africa, and rest of Middle East and Africa. The South America have been segmented into Brazil, Argentina and rest of South America. North America accounted for the largest market value but Asia-Pacific market is expected to grow at a higher CAGR during the forecast period. The emerging economies and new products with better efficacy will be a big opportunity for the market.

The key players in the market are 3S Bio, Amgen, Hoffmann La Roche, Johnson and Johnson, BioSidus, Biocon, Hospira, Intas Pharmaceuticals, Celltrion, and Teva Pharmaceuticals

Key Deliverables:

Market analysis for the Global Erythropoietin stimulating agents market, with region specific assessments and competition analysis.

Market definition along with the identification of key drivers and restraints.

Identification of factors instrumental in changing the market scenarios, rising prospective opportunities, and identification of key companies that can influence this market on regional scale

Extensively researched competitive landscape section with profiles of major companies along with their market shares

Identification and analysis of the macro and micro factors that affect the Erythropoietin stimulating agents market

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information

A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market

Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
Note: Product cover images may vary from those shown
2 of 3
1. Introduction
1.1 Study deliverables
1.2 Market definition
1.3 Study assumptions
2. Research approach and methodology
2.1 Introduction
2.2 Analysis methodology
2.3 Study timeline
2.4 Study phases
2.4.1 Secondary research
2.4.2 Discussion guide
2.4.3 Market engineering & econometric model
2.4.4 Expert validation
3. Executive summary
4. Key inferences
5. Market overview and industry trends
5.1 Current market scenario
5.2 Porter's five forces
5.2.1 Bargaining power of suppliers
5.2.2 Bargaining power of consumers
5.2.3 Threat to new entrants
5.2.4 Threat to substitute products and services
5.2.5 Competitive rivalry within the industry
6. Market drivers, restraints, challenges, and opportunities
6.1 Market drivers
6.1.1 Rising Number of Surgeries
6.1.2 New approvals of anesthetic drugs
6.1.3 Increase in number of cosmetic surgeries
6.2 Market restraints
6.2.1 Side effects of general anesthetics
6.2.2 Lack of skilled anesthesiologist
6.2.3 Regulatory Issues
6.3 Market opportunities
6.4 Market challenges
7. Market segmentation
7.1 Drugs
7.1.1 Propofol
7.1.2 Sevoflurane
7.1.3 Desflurane
7.1.4 Isoflurane
7.1.5 Dexmedetomidine
7.1.6 Remifentanil
7.1.7 Midazolam
7.1.8 Others
7.2 By route of administration
7.2.1 Inhalation
7.2.2 Injection
8. Market segmentation by geography
8.1 North America
8.1.1 United States
8.1.2 Canada
8.1.3 Mexico
8.2 Europe
8.2.1 Germany
8.2.2 United Kingdom
8.2.3 France
8.2.4 Italy
8.2.5 Spain
8.2.6 Rest of Europe
8.3 Asia-Pacific (APAC)
8.3.1 China
8.3.2 Japan
8.3.3 India
8.3.4 Australia & New Zealand
8.3.5 South Korea
8.3.6 Rest of Asia-Pacific
8.4 Middle East & Africa
8.4.1 GCC
8.4.2 South Africa
8.4.3 Rest of MENA
8.5 South America
8.5.1 Brazil
8.5.2 Argentina
8.5.3 Rest of South America
9. Competitive landscape
9.1 Merger and acquisition analysis
9.2 New Product Launches
9.3 Agreements, Collaborations, and Partnerships
10. Company profiles
10.1 Baxter
10.2 Hospira
10.3 Abbott
10.4 Astra Zeneca
10.5 Roche
10.6 Novartis
10.7 Pfizer
10.8 Eisai
10.9 Fresenius Se & Co.
10.10 Hikma Pharmaceuticals
11. Future outlook for investment opportunity
12. Analyst outlook of the market
Note: Product cover images may vary from those shown
3 of 3